The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis

Multiple Sclerosis Journal

Volumn 17, Issue 3, 2011, Pages 281-288

  Rossi, Silvia ^a,b   Buttari, Fabio ^a,b   Studer, Valeria ^a,b   Motta, Caterina ^a,b   Gravina, Paolo ^c   Castelli, Maura ^a,b   Mantovani, Vilma ^d   De Chiara, Valentina ^a,b   Musella, Alessandra ^a,b   Fiore, Stefania ^a,b   Masini, Silvia ^e   Bernardi, Giorgio ^a,b   MacCarrone, Mauro ^b,f   Bernardini, Sergio ^c,g   Centonze, Diego ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e SAN FILIPPO NERI HOSPITAL   (Italy)

^f UNIVERSITY OF TERAMO   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

BREMS; CNR1; excitotoxicity; neurodegeneration; progression index; treatment failure

Indexed keywords

ADENOSINE; CANNABINOID 1 RECEPTOR; THYMINE;

ARTICLE; BAYES THEOREM; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE REPEAT;

EID: 79953184306     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510388680     Document Type: Article

References (42)

1. Compston A. and Coles A. Multiple sclerosis. Lancet 2008 ; 372: 1502 1517.
2. Rudick RA and Polman CH Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol 2009 ; 8: 545 559.
3. Pryce G., Ahmed Z., Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003 ; 126: 2191 2202.
4. Lyman WD, Sonett JR, Brosnan CF, Elkin R. and Bornstein MB Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 1989 ; 23: 73 81.
5. Wirguin I., Mechoulam R., Breuer A., Schezen E., Weidenfeld J. and Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 1994 ; 28: 209 214.
6. Arévalo-Martin A., Vela JM, Molina-Holgado E., Borrell J. and Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003 ; 23: 2511 2516.
7. Croxford JL and Miller SD Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest 2003 ; 111: 1231 1240.
8. Mestre L., Correa F., Arévalo-Martin A., Molina-Holgado E., Valenti M., Ortar G., et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005 ; 92: 1327 1339.
9. Mestre L., Docagne F., Correa F., Lorìa F., Hernangòmez M., Borrell J., et al. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 2009 ; 40: 258 266.
10. Ortega-Gutierrez S., Molina-Holgado E., Arévalo-Martin A., Correa F., Viso A., Lòpez-Rodrìguez ML, et al. Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis. FASEB J 2005 ; 19: 1338 1343.
11. Croxford JL, Pryce G., Jackson SJ, Ledent C., Giovannoni G., Pertwee RG, et al. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol 2008 ; 193: 120 129.
12. Webb M., Luo L., Ma JY and Tham CS Genetic deletion of fatty acid amide hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. Neurosci Lett 2008 ; 439: 106 110.
13. Rossi S., Furlan R., De Chiara V., Musella A., Lo Giudice T., Mataluni G., et al. Exercise attenuates the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis. Neurobiol Dis 2009 ; 36: 51 59.
14. Zhang M., Martin BR, Adler MW, Razdan RJ, Kong W., Ganea D., et al. Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol 2009 ; 4: 249 259.
15. Shakespeare DT, Boggild M. and Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003 ; 4: CD001332.
16. Zajicek J., Fox P., Sanders H., Wright D., Vickery J., Nunn A., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003 ; 362: 1517 1526. (Pubitemid 37410189)
17. Centonze D., Mori F., Koch G., Buttari F., Codecà C., Rossi S., et al. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 2009 ; 30: 531 534.
18. Woolmore J., Stone M., Holley S., Jenkinson P., Ike A., Jones P., et al. Polymorphisms of the cannabinoid 1 receptor gene and cognitive impairment in multiple sclerosis. Mult Scler 2008 ; 14: 177 182. (Pubitemid 351639625)
19. Zhang PW, Ishiguro H., Ohtsuki T., Hess J., Carillo F., Walther D., et al. Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 2004 ; 9: 916 931. (Pubitemid 39381956)
20. Li YC, Korol AB, Fahima T. and Nevo E. Microsatellites within genes: structure, function, and evolution. Mol Biol Evol 2004 ; 21: 991 1007. (Pubitemid 38658207)
21. Li T., Liu X., Zhu ZH, Zhao J., Hu X., Ball DM, et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000 ; 5: 128 130. (Pubitemid 30229425)
22. Covault J., Gelernter J. and Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol Psychiatry 2001 ; 6: 501 502. (Pubitemid 32772558)
23. Ballon N., Leroy S., Roy C., Bourdel MC, Charles-Nicolas A., Krebs MO, et al. (AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics J 2006 ; 6: 126 130.
24. López-Moreno JA, López-Jiménez A., Gorriti MA and de Fonseca FR Functional interactions between endogenous cannabinoid and opioid systems: focus on alcohol, genetics and drug-addicted behaviors. Curr Drug Targets 2010 ; 11: 406 428.
25. Barrero FJ, Ampuero I., Morales B., Vives F., de Dios Luna Del Castillo J., Hoenicka J., et al. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J 2005 ; 5: 135 141. (Pubitemid 40468120)
26. Siegfried Z., Kanyas K., Latzer Y., Karni O., Bloch M., Lerer B., et al. Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. Am J Med Genet B Neuropsychiatr Genet 2004 ; 125B: 126 130. (Pubitemid 38141416)
27. Ujike H., Takaki M., Nakata K., Tanaka Y., Takeda T., Kodama M., et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002 ; 7: 515 518. (Pubitemid 34712904)
28. Martínez-Gras I., Hoenicka J., Ponce G., Rodrìguez- Jiménez R., Jiménez-Arriero MA, Pérez-Hernandez E., et al. AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci 2006 ; 256: 437 441. (Pubitemid 44584060)
29. Ramil E., Sánchez AJ, González-Pérez P., Rodrìguez-Antiguedad A., Gòmez-Lozano N., Ortiz P., et al. The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain. Mult Scler 2010 ; 16: 139 146.
30. Polman CH, Reingold SC, Edan G., Filippi M., Hartung HP, Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005 ; 58: 840 846. (Pubitemid 41746873)
31. Bergamaschi R., Quaglini S., Trojano M., Amato MP, Tavazzi E., Paolicelli D., et al. Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. J Neurol Neurosurg Psychiatry 2007 ; 78: 757 759. (Pubitemid 46998854)
32. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444 1452. (Pubitemid 14237132)
33. Roxburgh RH Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005 ; 64: 1144 1151.
34. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J., et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999 ; 122: 871 882. (Pubitemid 29219261)
35. Eljaschewitsch E., Witting A., Mawrin C., Lee T., Schmidt PM, Wolf S., et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006 ; 49: 67 79. (Pubitemid 43017186)
36. Centonze D., Bari M., Rossi S., Prosperetti C., Furlan R., Fezza F., et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007 ; 130: 2543 2553. (Pubitemid 47511703)
37. Jean-Gilles L., Feng S., Tench CR, Chapman V., Kendall DA, Barrett DA, et al. Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 2009 ; 287: 212 215.
38. Baker D., Pryce G., Croxford JL, Brown P., Pertwee RG, Makriyannis A., et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001 ; 15: 300 302.
39. Baker D., Pryce G., Giovannoni G. and Thompson AJ The therapeutic potential of cannabis. Lancet Neurol 2003 ; 2: 291 298. (Pubitemid 38368569)
40. Killestein J. and Uitdehaag BM Cannabinoids in multiple sclerosis: urgent need for long term trials. J Neurol Neurosurg Psychiatry 2005 ; 76: 1612. (Pubitemid 41697620)
41. Pertwee RG Cannabinoids and multiple sclerosis. Pharmacol Ther 2002 ; 95: 165 174. (Pubitemid 35232134)
42. Leray E., Yaouanq J., Le Page E., Coustans M., Laplaud D., Oger J. and Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010 ; 133: 1900 1913.